Eliquis may be safer than Xarelto for patients with deep blood clots: Study

Ella Jeffries / beckershospitalreview - Patients taking blood thinner Eliquis had a lower risk of clinically relevant bleeding than those taking Xarelto, a recent study found. Researchers enrolled 2,760 patients with venous thrombosis — blood clots in the veins of the legs or lungs — and random…

AI Summary: A direct comparison trial found apixaban (Eliquis) produced a lower rate of clinically relevant bleeding than rivaroxaban (Xarelto) in patients treated for venous thromboembolism while preserving efficacy against clots. The results offer prescribers clear comparative safety data that could influence anticoagulant selection and guideline recommendations.

---

Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61

Related Stories

---

Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128

Zoliflodacin shows promise as single-dose treatment for gonorrhea / 5 months

PAXG regimen shows superior event‐free survival in early pancreatic cancer / 6 months

Therapeutic HPV vaccine slows throat tumors in preclinical tests / 3 months

Gene‑editing trials explore one‑time fix for high cholesterol / 3 months

Bayer’s Asundexian Reduces Stroke Risk by 26% in Phase 3 Trial / 3 months

Eikon Therapeutics raises $381M IPO for cancer drug advancement / 3 months

Aktis Oncology IPO boosts radiopharmaceutical pipeline / 4 months